KURA

Kura Oncology Reports Fourth Quarter and Full Year 2021 Financial Results

Retrieved on: 
Thursday, February 24, 2022
Retinoic acid syndrome, Risk, GLOBE, Therapy, Population, HRAS, Webcast, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Head, Pharmacokinetics, NPM1, Breakthrough therapy, Investment, Security (finance), Hand, Novartis, Drug resistance, HNSCC, Research, Neoplasm, Postcholecystectomy syndrome, AML, Company, KURA, Safety, American Association, U.S. Securities and Exchange Commission, FTI, AACR, Food, Acute myeloid leukemia, IND, News, FDA, Cancer, Nasdaq, KMT2A, Patient, Large-cell lung carcinoma, Association, Program, Tipifarnib, Pharmaceutical industry, NSCLC

ET

Key Points: 
  • ET
    SAN DIEGO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported fourth quarter and full year 2021 financial results and provided a corporate update.
  • Research and development expenses for the fourth quarter of 2021 were $21.0 million, compared to $17.5 million for the fourth quarter of 2020.
  • General and administrative expenses for the fourth quarter of 2021 were $12.1 million, compared to $8.8 million for the fourth quarter of 2020.
  • Net loss for the fourth quarter of 2021 was $32.7 million, compared to a net loss of $26.2 million for the fourth quarter of 2020.

Kura Oncology to Report Fourth Quarter and Full Year 2021 Financial Results

Retrieved on: 
Thursday, February 17, 2022
Patient, Webcast, Cancer, Tipifarnib, Company, SAN, Nasdaq, NPM1, Neoplasm, HNSCC, HRAS, FTI, KMT2A, KURA, Breakthrough therapy, GLOBE, Pharmaceutical industry

SAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2021 financial results after the close of U.S. financial markets on Thursday, February 24, 2022.

Key Points: 
  • SAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2021 financial results after the close of U.S. financial markets on Thursday, February 24, 2022.
  • ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.
  • Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer.
  • The Company is also developing KO-2806, a next-generation FTI, which is intended to target innovative biology and larger oncology indications through rational combinations.

Kura Oncology to Participate in SVB Leerink Global Healthcare Conference

Retrieved on: 
Thursday, February 10, 2022
GLOBE, KURA, Neoplasm, HRAS, AML, Conference, NPM1, Investor, Company, Cancer, Breakthrough therapy, Patient, HNSCC, KMT2A, Tipifarnib, Nasdaq, SAN, Pharmaceutical industry

SAN DIEGO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the 11th Annual SVB Leerink Global Healthcare Conference.

Key Points: 
  • SAN DIEGO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the 11th Annual SVB Leerink Global Healthcare Conference.
  • Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 12:40 p.m. PT / 3:40 p.m.
  • Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer.
  • For additional information about Kura, please visit the Companys website at www.kuraoncology.com .

Kura Oncology Expands Leadership Team with Key Promotions

Retrieved on: 
Tuesday, February 1, 2022
Risk, University, Bioethics, Research, Cancer, Controller, California State University, GLOBE, T-cell lymphoma, Senior, MBA, U.S. Securities and Exchange Commission, Drug, Thomas Jefferson University, Roche, Accounting, ISTA Pharmaceuticals, KURA, LabCorp, Company, Medicine, Cost accounting, Drug development, Security (finance), Internal audit, Defense Finance and Accounting Service, California State University San Marcos, Mayo Collaborative Services v. Prometheus Laboratories, Inc., Communication, Neoplasm, KMT2A, San Diego State University, Corporate communication, Bachelor of Science, Executive, Tipifarnib, HRAS, Bausch Health, News, Public relations, Nasdaq, Safety, Patient, SAN, SEC, Kyowa Hakko Kirin, Breakthrough therapy, NPM1, HNSCC, Family, Therapy, AML, Management, Pharmaceutical industry, Finance, Science, Favrile glass

I am thrilled to announce the promotions of our colleagues Mollie, Pete and Tom, said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.

Key Points: 
  • I am thrilled to announce the promotions of our colleagues Mollie, Pete and Tom, said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.
  • These promotions reflect their significant contributions toward advancing our strategic objectives, as well as our confidence in their ability to deliver results and help lead Kura into our next exciting phase of growth.
  • Mollie Leoni, M.D., joined Kura as Vice President, Clinical Development in February 2020 with extensive drug development experience focused in oncology and orphan diseases.
  • Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer.

Kura Oncology Receives FDA Authorization to Proceed with Phase 1b Study of KO-539 in Acute Myeloid Leukemia

Retrieved on: 
Thursday, January 20, 2022
Patient, Research, News, SAN, Tipifarnib, SEC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, KURA, HRAS, Safety, Postcholecystectomy syndrome, AML, GLOBE, Breakthrough therapy, Acute myeloid leukemia, HNSCC, NPM1, U.S. Securities and Exchange Commission, Nasdaq, Pharmacokinetics, Company, Therapy, Cancer, Food, Neoplasm, Risk, FDA, Security (finance), KMT2A, Pharmaceutical industry

SAN DIEGO, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the KOMET-001 Phase 1b study of KO-539 in patients with relapsed or refractory acute myeloid leukemia (AML). The partial clinical hold was lifted following agreement with the FDA on the Company’s mitigation strategy for differentiation syndrome, a known adverse event related to differentiating agents in the treatment of AML.

Key Points: 
  • Activities to resume patient screening are underway, and we look forward to expediting enrollment of patients in the Phase 1b study and determining the recommended Phase 2 dose for KO-539 in the coming months.
  • KOMET-001 (Kura Oncology Menin Inhibitor Trial) is a Phase 1/2, first-in-human, open-label trial to determine the safety, tolerability and anti-tumor activity of KO-539 in patients with refractory or relapsed AML.
  • Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer.
  • The Company is also developing KO-2806, a next-generation farnesyl transferase inhibitor, which is intended to target innovative biology and larger oncology indications through rational combinations.

Kura Oncology Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma

Retrieved on: 
Thursday, December 16, 2021
U.S. Securities and Exchange Commission, FDA, Prognosis, Tipifarnib, AML, Company, The Cancer Genome Atlas, Population, KURA, SAN, Nasdaq, EGFR, Cancer, Survival, SEC, Head, Immunotherapy, Breakthrough therapy, Oncogene, Risk, NPM1, Research, Safety, Novartis, Patient, Cetuximab, Neoplasm, TCGA, Therapy, Security (finance), Patent, KMT2A, PI3K, GLOBE, HRAS, Drug resistance, PIK3CA, News, Pharmaceutical industry, HNSCC

SAN DIEGO, Dec. 16, 2021 (GLOBE NEWSWIRE) --  Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced dose administration for the first patient in KURRENT, the Company’s Phase 1/2 clinical trial of tipifarnib in combination with alpelisib in patients with HRAS- and/or PIK3CA-dependent head and neck squamous cell carcinoma (HNSCC).

Key Points: 
  • Tipifarnib is Kuras farnesyl transferase inhibitor drug candidate currently in a registration-directed trial as a monotherapy in patients with HRAS mutant HNSCC.
  • Novartis alpelisib is an inhibitor of phosphatidylinositol-3-kinase (PI3K) with inhibitory activity predominantly against the PI3K isoform.
  • Earlier this year, Kura announced a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with HNSCC whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification.
  • Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide, accounting for more than 500,000 new cases each year.

Kura Oncology Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Lymphoma

Retrieved on: 
Monday, December 13, 2021
U.S. Securities and Exchange Commission, Food, AML, Company, KURA, Adult, Nasdaq, Progression-free survival, Fatigue, Biomarker, DOR, ORR, Cancer, HNSCC, SEC, Survival, Hematology, Breakthrough therapy, T-cell lymphoma, Neutropenia, Thrombocytopenia, Anemia, Lymphatic system, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Risk, Research, NPM1, Safety, Patient, Nausea, Therapy, Security (finance), Angioimmunoblastic T-cell lymphoma, Patent, KMT2A, Fast Track, GLOBE, ASH, HRAS, Tipifarnib, Mayo Clinic, News, Society, Diarrhea, Pharmaceutical industry, Janssen

SAN DIEGO, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced final results from a Phase 2 study of tipifarnib as a monotherapy in patients with relapsed or refractory T-cell lymphoma, including an overall response rate (ORR) of 56% and a median overall survival of 32.8 months in heavily pretreated patients with angioimmunoblastic T-cell lymphoma (AITL).

Key Points: 
  • The final results are being presented during an oral session today at the American Society of Hematology (ASH) Annual meeting in Atlanta.
  • A total of 65 patients with relapsed or refractory T-cell lymphoma were enrolled in the study, with a median of three prior regimens (range 1-8).
  • Tipifarnib was generally well-tolerated in this Phase 2 study, with adverse events consistent with its known safety profile.
  • This multi-center, single-arm, open-label Phase 2 study was designed to evaluate tipifarnib as a monotherapy in adult patients with relapsed or refractory T-cell lymphoma.

Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Menin Inhibitor KO-539 in Combination with Venetoclax

Retrieved on: 
Monday, December 13, 2021
U.S. Securities and Exchange Commission, Food, Poster, MEIS1, AML, Company, Azacitidine, KURA, SAN, Nasdaq, Venetoclax, Cancer, HNSCC, Survival, SEC, Breakthrough therapy, Risk, NPM1, Regulation of tobacco by the U.S. Food and Drug Administration, Research, Safety, Patient, Therapy, Security (finance), MD Anderson Cancer Center, FLT3, KMT2A, BCL2, GLOBE, ASH, Acute myeloid leukemia, HRAS, Tipifarnib, News, Society, Pharmaceutical industry

KO-539 has previously been shown to disrupt the menin-KMT2A/MLL protein-protein interaction, inducing differentiation and potent anti-leukemic activity in genetically defined preclinical models of AML.

Key Points: 
  • KO-539 has previously been shown to disrupt the menin-KMT2A/MLL protein-protein interaction, inducing differentiation and potent anti-leukemic activity in genetically defined preclinical models of AML.
  • These important findings highlight the molecular mechanisms of anti-leukemic activity for KO-539, suggest the potential for synergistic activity in combination, and support our development strategy to combine KO-539 with venetoclax in patients with AML.
  • Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer.
  • Such forward-looking statements include statements regarding, among other things, the efficacy, safety and therapeutic potential of KO-539, and the potential for KO-539 synergistic activity in combination.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kura Oncology, Inc. - KURA

Retrieved on: 
Wednesday, December 1, 2021
Patient, Pomerantz, News, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, LLP, Company, AML, Acute myeloid leukemia, GLOBE, FDA, Postcholecystectomy syndrome, KURA, NASDAQ, Food, Pharmaceutical industry

NEW YORK, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Kura Oncology, Inc. (Kura or the Company) (NASDAQ:KURA).

Key Points: 
  • NEW YORK, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Kura Oncology, Inc. (Kura or the Company) (NASDAQ:KURA).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Kura and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kura Oncology, Inc. - KURA

Retrieved on: 
Thursday, November 25, 2021
Patient, Pomerantz, News, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, LLP, Company, AML, Acute myeloid leukemia, GLOBE, FDA, Postcholecystectomy syndrome, KURA, NASDAQ, Food, Pharmaceutical industry

NEW YORK, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Kura Oncology, Inc. (Kura or the Company) (NASDAQ:KURA).

Key Points: 
  • NEW YORK, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Kura Oncology, Inc. (Kura or the Company) (NASDAQ:KURA).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Kura and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.